EGFR and non-small cell lung carcinoma: Although all generations of EGFR-TKIs have been proven to be very effective for NSCLC with common EGFR mutations, almost 5–25% of these patients do not experience a clinical benefit with these drugs due to intrinsic resistance [57,58].